Mukherjee will be succeeded by Erez Israeli, former president and CEO of Enzymotec. Israeli will join Dr. Reddy's on April 2, 2018, as chief operating officer and global head of generics and PSAI, based out of Hyderabad.
Prior to Enzymotec, he completed 23 years with Teva Pharmaceuticals Ltd., where he held several positions of responsibility including vice president marketing and sales for North America, vice president Asia Operations, president Teva API, group executive vice president, head of global quality, and president and CEO growth markets.
Dr. Reddy's is committed to providing affordable and innovative medicines through its three businesses - pharmaceutical services and active ingredients, global generics, and proprietary products.
The company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, and differentiated formulations.
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy's operates in markets across the globe, including the US, India, Russia and CIS countries, and Europe.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling